SITR1 cooperates with the activity regulator AROS to inhibit the acetylation of GSK3β, inactivating GSK3β, which weakens doxorubicin‐mediated apoptosis in neuroblastoma treatment, leading to tumour resistance.72 Here, GSK3B is linked to neoplasm.